{"nct_id":"NCT04303169","title":"Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-08","start_date":"2020-06-26","start_date_type":"ACTUAL","primary_completion_date":"2025-10-06","primary_completion_date_type":"ESTIMATED","completion_date":"2025-10-06","completion_date_type":"ESTIMATED","phases":["PHASE1","PHASE2"],"tickers":["MRK"]}